|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
ELISA was performed to detect EGF concentration in co-culture system of M2-like TAMs and OC cell lines.
|
31062668 |
2019 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that high serum HB-EGF concentrations were significantly associated with poor prognosis in a combined cohort of patients with all stages of ovarian cancer, as well as in a subset of patients with advanced disease.
|
28668900 |
2017 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER3 is a member of the epidermal growth factor family and was predominantly described as a negative prognostic factor in various solid tumors as well as in ovarian cancer.
|
27913862 |
2017 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, HB-EGF is a molecular target for the resistance of ovarian cancer to paclitaxel and CRM197 as a HB-EGF-targeted agent might be a chemosensitizing agent for paclitaxel-resistant ovarian carcinoma.
|
26572150 |
2016 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our data provide evidence that TNFR1 plays a critical role in ovarian cancer and show that the EGF induced signaling pathway is independent of the TNF-α triggering cascade signal.
|
26122654 |
2015 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacological inhibition of c-Myc reduced HB-EGF induced glycolytic enzymes implicating a major role of c-Myc in loss of HSulf-1 mediated altered glycolytic pathway in OVCA.
|
26378042 |
2015 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, to investigate the mechanisms of the regulation of tight junctions in ovarian cancers, ovarian cancer cell lines mucinous cystadenocarcinoma (MCAS) and serous cystadenocarcinoma (HUOA) were treated with EGF.
|
22544349 |
2012 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor (EGF) activation of the EGF receptor (EGFR) is an important mediator of cell migration, and aberrant signaling via this system promotes a number of malignancies including ovarian cancer.
|
22315226 |
2012 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that EGF and LPA both stimulate production of LPA by OVCAR3 and SKOV3 human ovarian cancer cell lines.
|
19864325 |
2010 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to appraise the association between EGF gene A61G polymorphism with ovarian cancer susceptibility.
|
19144868 |
2009 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
HB-EGF also plays a pivotal role in the progression of ovarian cancer.
|
18852147 |
2008 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our objective was to correlate EGFR over-expression and growth inhibition, by EGF receptor inhibitors, in ovarian cancer.
|
18423824 |
2008 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The epidermal growth factor (EGF) and EGF receptor (EGFR) family are often overexpressed in various human cancers including ovarian cancer.
|
17045920 |
2006 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation.
|
15921680 |
2005 |
|
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HB-EGF expression was significantly increased in advanced ovarian cancer compared with that in normal ovaries (P < 0.01).
|
16000575 |
2005 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGF- and cell-cycle-regulated STAG1/PMEPA1/ERG1.2 belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer.
|
14639658 |
2003 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that EGF-related peptides function as autocrine growth factors in ovarian carcinoma cells, and that they might represent targets for experimental therapy of ovarian carcinoma.
|
10811499 |
2000 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
All these data are consistent with E2 increasing production of TGFalpha in ER-positive ovarian cancer and this in turn acting through the EGF receptor to modulate growth in an autocrine manner.
|
9605408 |
1998 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two of five EGF receptor-negative ovarian cancers implanted and grew in both control and Sx animals.
|
7954262 |
1994 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, some proto-oncogenes such as the EGF receptor (erbB) and the M-CSF receptor (fms) are expressed along with their respective ligands in some ovarian cancers.
|
1500387 |
1992 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGF-R or TGFa expressing ovarian carcinomas had a high response rate to chemotherapy, whereas the EGF-R or TGFa negative tumors mostly exhibit a no change or progressive disease behaviour.
|
1746909 |
1992 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGF-R+ ovarian carcinomas responded significantly better to chemotherapy.
|
2285597 |
1990 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGF-R positive (EGF-R(+)) ovarian carcinomas had a significantly higher response rate to chemotherapy.
|
2697181 |
1990 |